⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonaldehyde SCHEMBL16287 | 0.85 | — | — | |
| Malonaldehyde SCHEMBL10949336 | 0.85 | ALDH1A1 (0.42) | — | |
| Malonaldehyde SCHEMBL4259871 | 0.82 | — | — | |
| Malonaldehyde SCHEMBL2429722 | 0.80 | — | — | |
| Malonaldehyde SCHEMBL3130097 | 0.80 | — | — | |
| Malonaldehyde SCHEMBL7515120 | 0.80 | — | — | |
| Malonaldehyde SCHEMBL3334683 | 0.80 | — | — | |
| Malonaldehyde SCHEMBL9754363 | 0.80 | — | — | |
| Malonaldehyde SCHEMBL825464 | 0.80 | — | — | |
| Malonaldehyde SCHEMBL8182493 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230075784-A1 | ANTI-MAA LMMUNOGLOBULIN ISOTYPES IN INFLAMMATORY BOWEL DISEASE: NOVEL DIAGNOSTIC IMPLICATIONS FOR ULCERATIVE COLITIS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-03-09 | — | — | US | claimed |
| WO-2021146562-A1 | ANTI-MAA IMMUNOGLOBULIN ISOTYPES IN INFLAMMATORY BOWEL DISEASE: DIAGNOSTIC IMPLICATIONS FOR ULCERATIVE COLITIS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-07-22 | — | — | WO | claimed |
| US-20200249224-A1 | BIOMARKER FOR CORONARY ARTERY DISEASE | DEPARTMENT OF VETERANS AFFAIRS | 2020-08-06 | — | — | US | claimed |
| US-20180313826-A1 | BIOMARKER FOR CORONARY ARTERY DISEASE | DEPARTMENT OF VETERANS AFFAIRS | 2018-11-01 | — | — | US | claimed |
| EP-0873136-A4 | HIGH FLUORESCENCE SPECIFIC IMMUNE ENHANCING FACTOR AND METHODS OF USE FOR SAME | UNIV NEBRASKA (US) | 2001-11-07 | — | — | EP | claimed |
| US-6120777-A | MALONDIALDEHYDE-ACETALDEHYDE ADDUCT | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2000-09-19 | — | — | US | claimed |
| EP-0873136-A2 | HIGH FLUORESCENCE SPECIFIC IMMUNE ENHANCING FACTOR AND METHODS OF USE FOR SAME | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1998-10-28 | — | — | EP | claimed |
| WO-1997015324-A1 | HIGH FLUORESCENCE SPECIFIC IMMUNE ENHANCING FACTOR AND METHODS OF USE FOR SAME | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-05-01 | — | — | WO | claimed |
| EP-4714979-A1 | BIASED COMPLEMENT INHIBITORY HYBRID PROTEIN | Longbio Pharma (Suzhou) Co., Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077039-A1 | ANTI-HUMAN COMPLEMENT C5 ANTIBODY AND FUSION PROTEIN THEREOF | LONGBIO PHARMA SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | disclosed |
| US-12571795-B2 | Anti-MAA immunoglobulin isotypes in inflammatory bowel disease: novel diagnostic implications for ulcerative colitis | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250257106-A1 | COMPLEMENT-INHIBITING HYBRID PROTEIN | LONGBIO PHARMA (SUZHOU) CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| EP-4582445-A1 | ANTI-HUMAN COMPLEMENT C5 ANTIBODY AND FUSION PROTEIN THEREOF | Longbio Pharma (Suzhou) Co., Ltd. (CN) | 2025-07-09 | — | — | EP | disclosed |
| EP-4509521-A1 | COMPLEMENT-INHIBITING HYBRID PROTEIN | Longbio Pharma (Suzhou) Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| WO-2021146562-A1 | ANTI-MAA IMMUNOGLOBULIN ISOTYPES IN INFLAMMATORY BOWEL DISEASE: DIAGNOSTIC IMPLICATIONS FOR ULCERATIVE COLITIS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-07-22 | — | — | WO | disclosed |
| CN-112409475-A | Method for synthesizing Malonaldehyde Acetaldehyde Adduct (MAA) | 武汉戴安生物技术有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200249224-A1 | BIOMARKER FOR CORONARY ARTERY DISEASE | DEPARTMENT OF VETERANS AFFAIRS | 2020-08-06 | — | — | US | disclosed |
| US-6814951-B1 | HIGH LEVELS OF ACETALDEHYDE AND PRODUCTION OF MALONDIALDEHYDE FOLLOWING ALCOHOL INGESTION CHEMICALLY COMBINE IN A SYNERGISTIC MANNER CREATING A NEW HYBRID ADDUCT FORMED WITH HEPATIC PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2004-11-09 | — | — | US | disclosed |
| US-5939535-A | Acetaldehyde and malondialdehyde protein adducts | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1997015599-A1 | NOVEL ACETALDEHYDE AND MALONDIALDEHYDE PROTEIN ADDUCTS AS MARKERS FOR ALCOHOL LIVER DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1997-05-01 | — | — | WO | disclosed |